Celularity
About:
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Website: https://www.celularity.com
Twitter/X: celularity
Top Investors: Alumni Ventures, Human Longevity, Section 32, Heritage Group, Castor Ventures
Description:
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
$400M
$50M to $100M
Florham Park, New Jersey, United States
2017-09-01
media(AT)celularity.com
Andrew L. Pecora, Peter Diamandis, Robert J. Hariri
101-250
2022-05-26
Public
© 2025 bioDAO.ai